Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 5
2004 4
2005 3
2006 4
2007 5
2008 10
2009 3
2010 1
2011 1
2013 7
2014 4
2015 7
2016 17
2017 18
2018 23
2019 26
2020 25
2021 36
2022 36
2023 40
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

250 results

Results by year

Filters applied: . Clear all
Page 1
Risankizumab as a Therapeutic Approach for Recalcitrant Pyoderma Gangrenosum.
Michelucci A, Manzo Margiotta F, Granieri G, Salvia G, Fidanzi C, Bevilacqua M, Panduri S, Romanelli M, Dini V. Michelucci A, et al. Among authors: romanelli m. Adv Skin Wound Care. 2024 May 1;37(5):276-279. doi: 10.1097/ASW.0000000000000129. Adv Skin Wound Care. 2024. PMID: 38648242
Clinical Features and Response to Treatment in Elderly Subjects Affected by Hidradenitis Suppurativa: A Cohort Study.
Antonelli F, Ippoliti E, Rosi E, Moltrasio C, Malvaso D, Botti E, Abeni D, Dini V, Cannizzaro MV, Bruni M, Di Nardo L, Fargnoli MC, Romanelli M, Fania L, Bianchi L, Marzano AV, Prignano F, Peris K, Chiricozzi A. Antonelli F, et al. Among authors: romanelli m. J Clin Med. 2023 Dec 18;12(24):7754. doi: 10.3390/jcm12247754. J Clin Med. 2023. PMID: 38137823 Free PMC article.
International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: A post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab.
Zouboulis CC, Prens EP, Sayed CJ, Molina-Leyva A, Bettoli V, Romanelli M, Szepietowski JC, Martinez AL, Kasparek T, Lobach I, Wozniak MB, Ortmann CE, Thomas N, Bachhuber T, Ravichandran S, Tzellos T. Zouboulis CC, et al. Among authors: romanelli m. J Eur Acad Dermatol Venereol. 2023 Dec 6. doi: 10.1111/jdv.19681. Online ahead of print. J Eur Acad Dermatol Venereol. 2023. PMID: 38058224 No abstract available.
Efficacy of risankizumab after intra-class switching between anti IL-23 antagonists: a multi-center, retrospective, real-life observation.
Manzo Margiotta F, Michelucci A, Capalbo E, Ricceri F, Rosi E, Rossari S, Magnano M, Savarese I, Milanesi N, Simoni B, Romanelli M, Rubegni P, DI Cesare A, Panduri S, Pescitelli L, Trovato E, Prignano F. Manzo Margiotta F, et al. Among authors: romanelli m. Ital J Dermatol Venerol. 2024 Feb;159(1):64-65. doi: 10.23736/S2784-8671.23.07648-X. Epub 2023 Nov 23. Ital J Dermatol Venerol. 2024. PMID: 37997317 No abstract available.
250 results